GlassScriptPhysician profile
Georgios Pongas
NPI 1487974770
$15,645.27
in general payments reported to CMS, 2019-2025
19 companies · $2,583 in 2025
The $2,583 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $490 · 2022: $693 · 2023: $918 · 2024: $11K · 2025: $2,583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $1,475 · Travel and Lodging: $913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,075.00 |
| Food and Beverage | $1,474.50 |
| Travel and Lodging | $912.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $10,691.50 | 2024 | |
| Beigene USA, INC. | $2,762.74 | 2022-2025 | Brukinsa |
| Astrazeneca Pharmaceuticals LP | $547.01 | 2023-2025 | Calquence |
| Beigene, LTD. | $450.00 | 2020 | |
| Beone Medicines USA, INC. | $267.43 | 2025 | Brukinsa |
| Genentech, INC. | $180.63 | 2022-2025 | Lunsumio |
| Acrotech Biopharma INC. | $129.95 | 2025 | Beleodaq |
| Janssen Biotech, INC. | $127.15 | 2023-2024 | Carvykti, Imbruvica, Tecvayli |
| Kyowa Kirin, INC. | $114.97 | 2024-2025 | Poteligeo |
| Seagen INC. | $101.81 | 2020-2022 | |
| Genmab U.S., INC. | $93.06 | 2023 | Epkinly |
| Genentech USA, INC. | $61.42 | 2023 | Columvi, Polivy, Venclexta |
| Novartis Pharmaceuticals Corporation | $44.09 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.75 | 2024 | Ninlaro |
| Genzyme Corporation | $21.93 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $17.03 | 2024 | |
| Celgene Corporation | $11.80 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Georgios Pongas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.